Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Merck & Co., Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Merck & Co., Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Merck & Co., Inc.
  • The company's enterprise value to sales, at 4.74 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Merck & Co., Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Merck & Co., Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Merck & Co., Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Merck & Co., Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Merck & Co., Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
29TCr
A
88TCr
A
58TCr
BBB
39TCr
AA
32TCr
AA
30TCr
A
29TCr
AAA
20TCr
A
18TCr
AAA
17TCr
A
Average 35.94TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Ratings Merck & Co., Inc.
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW